BioSpace News Archive

Avivagen Inc., a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, has announced its unaudited financial results for the first quarter of 2023.

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today reported financial results for fourth quarter and full year 2022 and provided a business update.

Harvard Bioscience, Inc. announced that Chairman and Chief Executive Officer Jim Green will present and host one-on-one meetings with investors at the Sidoti Virtual Investor Conference taking place on March 22-23, 2023.

Pfizer Inc. and Astellas Pharma Inc. announced positive topline results from the Phase 3 EMBARK trial evaluating XTANDI® in men with non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence.

Kelyniam Global, a maker of custom cranial implants, announced results for its year ended December 31, 2022.

Trevi Therapeutics, Inc. (Nasdaq: TRVI) today announced financial results for the quarter and year ended December 31, 2022, as well as provided business updates.

Geron Corporation (Nasdaq: GERN) today reported business updates, upcoming milestones and financial results for the fourth quarter and year ended December 31, 2022.

Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”) today provided a business update and reported financial results for the fiscal 2023 third quarter ended January 31, 2023.

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”) today announced financial results for its fourth quarter and full-year 2022, and provided a corporate update.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) today announced that at its late cycle meeting for the SRP-9001 (delandistrogene moxeparvovec) biologics license application (BLA), the U.S. Food and Drug Administration’s Office of Therapeutics (OTP) has determined that an advisory committee meeting will be held for SRP-9001 in advance of the May 29, 2023 regulatory action date.